BioXcel Therapeutics (NASDAQ:BTAI) Now Covered by Rodman & Renshaw

Research analysts at Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics (NASDAQ:BTAI) in a report issued on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $65.00 price target on the stock.

A number of other equities research analysts also recently commented on BTAI. Bank of America reiterated an “underperform” rating and issued a $4.00 price objective (down previously from $112.00) on shares of BioXcel Therapeutics in a report on Tuesday, January 7th. HC Wainwright lowered their price target on BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Finally, Canaccord Genuity Group lowered their price target on BioXcel Therapeutics from $112.00 to $80.00 and set a “buy” rating for the company in a report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, BioXcel Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $42.60.

BioXcel Therapeutics Trading Up 9.8 %

BTAI stock traded up $0.22 during trading on Wednesday, hitting $2.42. The company had a trading volume of 1,300,885 shares, compared to its average volume of 1,143,074. The company has a fifty day moving average price of $3.76 and a two-hundred day moving average price of $6.83. The company has a market cap of $7.74 million, a P/E ratio of -0.07 and a beta of 0.89. BioXcel Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $49.58.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BTAI. Geode Capital Management LLC boosted its position in shares of BioXcel Therapeutics by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock worth $117,000 after buying an additional 13,922 shares during the period. Wells Fargo & Company MN boosted its position in shares of BioXcel Therapeutics by 7.5% during the fourth quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after buying an additional 13,952 shares during the period. Northern Trust Corp boosted its position in shares of BioXcel Therapeutics by 81.4% during the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after buying an additional 33,161 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of BioXcel Therapeutics by 203.9% during the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after buying an additional 48,336 shares during the period. 30.68% of the stock is owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.